Oncology company Novocure (NASDAQ: NVCR) announced on Wednesday the success of its phase 3 METIS clinical trial, revealing a significant improvement in time to intracranial progression for non-small cell lung cancer (NSCLC) patients treated with Tumor Treating Fields (TTFields) therapy alongside supportive care.
Patients experienced a median time to intracranial progression of 21.9 months, compared to 11.3 months for those receiving supportive care alone. The treatment was well-tolerated with sustained quality of life and neurocognitive function.
METIS, involving 298 patients, demonstrated the efficacy of TTFields therapy in treating 1-10 brain metastases from NSCLC post-stereotactic radiosurgery.
Novocure intends to submit the data to regulatory authorities and publish findings in a peer-reviewed journal.
Brain metastases are common in NSCLC patients, affecting quality of life and prognosis. TTFields therapy offers a promising treatment option with minimal neurocognitive adverse events.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation